On December 20, 2023, Hansoh Pharma, a Hong Kong-listed pharmaceutical company, announced that it had entered into a licensing agreement with multinational pharmaceutical company GSK. GSK will be granted an exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) for the development, manufacturing, and commercialization.Developed by Hansoh PharmaHS-20093。According to the agreement between both parties,The total amount of this transaction exceeds 1.7 billion US dollars, of which Hansoh Pharma will receive an upfront payment of 185 million US dollars and is eligible to receive milestone payments of up to 1.525 billion US dollars upon the achievement of related events for this product.。At the same time, after the commercialization of this product, GSK will also pay based on the global net sales outside mainland China, Hong Kong, Macao, and Taiwan regions.Hansoh PharmaTiered Royalties.HS-20093 is an antibody-drug conjugate (ADC) developed by Hansoh Pharma. It is a humanized IgG1 ADC, consisting of a fully humanized B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. HS-20093 can specifically bind to the B7-H3 protein, which is widely expressed on solid tumor cells.The B7 family is an important group of immune regulatory proteins, including 10 members such as B7-H1 and B7-H3, where B7-H1 is also known as PD-L1. The PD-L1 pathway has played a significant role in cancer immunotherapy, becoming a cornerstone class of drugs.A large number of existing studies have found that B7-H3 is widely expressed in various types of tumors, playing an important role in multiple processes such as tumorigenesis, development, and immune escape. It is associated with poor prognosis of tumors and has a lower expression level in normal human tissues, thus becoming a potential anti-cancer target.At the 2023 American Society of Clinical Oncology (ASCO), Hansoh Pharma announced the Phase I study results of HS-20093 in advanced solid tumors.Data shows,HS-20093 in various advanced solid tumors that have failed existing standard treatments or are intolerant to standard treatmentsThe subjects showed excellent anti-tumor efficacy: the average Objective Response Rate (ORR) was 30.0%, the Disease Control Rate (DCR) was 86.0%, and the median Progression-Free Survival (mPFS) was 5.4 months.Among them, it shows better efficacy in small cell lung cancer: In small cell lung cancer subjects, the ORR was 63.6%.All tumor responses occurred at the first efficacy assessment, with a mPFS of 4.7 months and a 3-month PFS rate of 72.7%.In addition, HS-20093 still demonstrated antitumor efficacy in small cell lung cancer subjects who had previously failed irinotecan treatment.Good preliminary research data is undoubtedly an important reason for attracting GSK to acquire this R&D pipeline.Two months ago, Hansoh Pharma had reached another major product licensing deal with GSK worth over $1.5 billion in total transaction value: Hansoh Pharma granted GSK the global rights outside of Greater China for its self-developed B7-H4 ADC project HS-20089. Hansohn Pharma will receive an upfront payment of $85 million and up to $1.485 billion in milestone payments.B7-H3 and B7-H4 are type I transmembrane proteins, belonging to the B7 family. Their abnormalities are associated with many diseases, such as colon cancer, breast cancer, liver cancer, and lung cancer, and have become new targets for immunotherapy.
So far, there are no FDA-approved treatments or drugs targeting B7-H3 and B7-H4, and pharmaceutical companies worldwide are fiercely competing in the race for these two targets.
Currently, the therapies under research targeting B7-H4 are mostly antibodies and ADC drugs, with a predominance in breast cancer and ovarian cancer.
In addition to Hansoh Pharma's HS-20089, the main products targeting this point include AZD8205 (ADC) developed by AstraZeneca, SGN-B8H4V (ADC) developed by Seagen, and PF-07260437 (B7H4/CD3 bispecific antibody) developed by Pfizer, etc. All of the above products are in Phase I clinical stage or preclinical stage.
On the same day that Hansoh Pharma reached a B7-H4 ADC collaboration with GSK, multinational pharmaceutical company Merck struck a BD collaboration with Daiichi Sankyo on ifinatamab (B7-H3 ADC), patritumab (HER3 ADC), and raludotatug (CDH6 ADC). Merck will pay up to a total of $22 billion, with an upfront payment of $4 billion (equivalent to over 190 billion yuan in total).
As a long-established pharmaceutical company in China, Hansoh Pharma has continued to increase its R&D investment in recent years. In the first half of 2023, Hansoh Pharma's R&D investment surged by 25.8% to reach 929 million yuan, accounting for 20.6% of its revenue.
Currently, Hansoh Pharma has more than 30 innovative drugs under development, involving over 40 clinical trials, demonstrating strong R&D momentum.
Disclaimer: The publication/reposting of this article is solely for the purpose of information dissemination, and does not represent the views of this official account or confirm the authenticity of its content. Any judgment made based on this content will be at your own risk.If there is any infringement, please inform us and we will delete it immediately!
Press and hold to follow this official account
Fan Group/Submission/Authorization/Advertisementetc.Please contact the Official Account Assistant.If you find this article interesting, please click here ↓
